AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

The pause is the latest blow to the U.K.’s biotech industry, which is still reeling from Merck’s recently announced R&D ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

Philips and Masimo are renewing their years-long collaboration in patient monitoring, with what they describe as an expanded ...

Researchers at Mass General Brigham in Boston have designed a custom gene editing technique that corrected the mutation ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. | Capsida Biotherapeutics has paused a ...

Since 2018, the U.K.’s pharmaceutical R&D investment has underperformed versus global trends, the ABPI said in its new ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...

As part of the decision, Merck said that it will vacate laboratories at the London Bioscience Innovation Centre and the ...

What’s the best way to spend $2 billion? That’s the pleasant problem facing oncology legend Brian Druker, M.D., as he ...